Biotech Breakthroughs: 5 Start-Ups to Watch in 2025

The world of biotechnology is continually evolving, with start-ups leading the charge in innovative solutions that promise to shape the future of healthcare. In 2025, a new wave of biotech companies is emerging with ground-breaking technologies aimed at treating some of the most pressing medical challenges. From regenerative therapies for liver diseases to cutting-edge cancer treatments and advancements in RNA-based therapies, these start-ups are not only pushing the boundaries of science but also offering hope for patients around the globe.   

We take a closer look at five life sciences start-ups to watch in 2025, each making significant strides in their respective fields and poised to make a lasting impact in the world of medicine.  

Resolution Therapeutics 

Resolution Therapeutics, a clinical stage biopharmaceutical company, spun out of Professor Stuart Forbes’ laboratory at Edinburgh University, is focused on empowering regenerative macrophage therapy to overcome inflammatory and fibrotic diseases. The company’s science is supported by previous clinical studies that have shown positive safety and efficacy results with utilising macrophage therapy for liver indications; hence the current focus of the company lies with end-stage liver disease, Cirrhosis. In this endeavour, Resolution Therapeutics is developing a first-in-class macrophage cell therapy product, RTX001, for patients at risk of hepatic decompensation, with a goal of preventing further decompensations and avoiding liver transplants. The company’s innovative science put them at the forefront of regenerative medicine.   

LoQus23 Therapeutics  

LoQus23 Therapeutics is a private biotechnology company co-founded by David Reynolds, CEO and Caroline Benn, CSO in 2019. The company is investigating the role of oral, small molecule therapies in slowing neurodegeneration in Huntington’s Disease, Myotonic dystrophy type 1 and other triplet repeat expansion diseases. In this effort, by targeting the DNA mismatch repair pathway for treatment of Huntington’s disease and other triplet repair diseases, the company is revolutionising drug discovery. As of October 2024, the company announced its successful completion of its Series A financing round at £35 million, which will be dedicated towards the pre-clinical development and initial clinical studies of its lead product, an allosteric small molecule MutSβ inhibitor. The talented team of researchers is working towards targeting this inhibitor, to slow down and halt the onset and progression of Huntington’s disease. LoQus23 Therapeutics aims to have this product in clinics by 2026.  

BiVictriX  

BiVictriX, a rapidly emerging biotechnology company, is applying a novel approach to unmask cancer cells and develop safer, more effective cancer therapies, with a special focus on selectivity, high potency and increased effectiveness. With the development of Bi-Cygni® Therapeutics – a novel platform aimed at leveraging the science of bispecific therapeutic approach with antibody drug conjugates (ADCs), the company is developing a pipeline of first-in-class therapeutics, with superior cancer selectivity and improved, safer dosing. The lead product, BVX001, is in the pipeline for IND submission and was recognized as an Orphan drug in April 2024, as a CD7 x CD33 bispecific ADC, focused on treating Acute Myeloid Leukaemia and other Heme malignancies. With the team’s core values rooted in ‘bench to beside translatability’, BiVictriX is dedicated to keeping patients at the centre of all their work and ensuring clinicians deliver safe and effective doses of cancer therapy.  

Abselion  

Abselion, started in a small laboratory at University of Cambridge in 2018, is on a mission to simplify protein quantification and help scientists accelerate commercialisation of biotherapeutics. The focus is on developing convenient and fast, yet flexible analytical tools with high accuracy, automation and the ability to produce actionable data at the point of need. Their award-winning Amperia system based on the Redox Electrochemical Detection (RED) technology is at the forefront of analytical equipment. The Amperia is a compact, bench-top equipment powered by RED technology, enabling researchers to quantify a variety of biomolecules like antibodies and adeno-associated viruses (AAVs). Abselion’s aim to streamline analytical assays in the process of drug discovery and development was supported by the company securing £6.6 million in Series A funding in December 2024, which will be dedicated towards expanding the abilities of the Amperia and getting it to market.  

SENISCA 

SENISCA is an award-winning biotechnology company spun out of the University of Exeter and is focused on pioneering RNA biology to treat age related diseases. The company’s understanding of the molecular basis of rejuvenation, enables them to produce treatments focused on the causes and not just the consequences of age-related diseases. Hence, SENISCA is developing druggable, oligonucleotide based therapeutic approaches, to reprogram senescent cells by targeting the fundamental factors of dysregulated splicing responsible for the senescent state. As of March 2024, SENISCA secured an additional £3.7 million funding, that will contribute towards its efforts in pre-clinical development of the senotherapeutic programme, targeting causes of age-related diseases via RNA splicing. SENISCA’s platform technology aims to ensure broad applicability in diseases of the eyes, joints, lungs and brain.  

Paving The Way  

As the challenging biotech landscape continues to evolve, these five start-ups represent the promise of transformative advancements in healthcare. Their cutting-edge approaches, from novel therapies for chronic diseases to breakthroughs in cancer treatment and drug discovery, are paving the way for a new era of medicine. With the support of innovative scientists and investment, these companies are well-positioned to make a significant impact, offering hope for patients and healthcare professionals alike.   

Wentworth Life-Sciences are a trusted partner to a range of start-ups to large corporates, offering flexible and affordable talent-sourcing services tailored to individual business needs. If you’re interested in hearing how we can support your growth, by finding you the right expertise and team, call +44 (0)1892 579870 or email james@wentworth.life   

-------------------------------------------------------------------------------------